LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Cerrado

Sector Salud

7.99 -1.11

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.98

Máximo

8.05

Métricas clave
By Trading Economics
BPA	-0.172
Margen de beneficio	-66.092
Empleados	536

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+92.11 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	41M 990M
Apertura anterior	9.1
Cierre anterior	7.99

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

308 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

6.1 / 7.65 Soporte y Resistencia

BioCryst Pharmaceuticals Inc Gráfico

Noticias Relacionadas

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept 2024, 18:15 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept 2024, 18:12 UTC

Principales Noticias

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept 2024, 17:44 UTC

Charlas de Mercado

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept 2024, 17:30 UTC

Charlas de Mercado

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept 2024, 17:30 UTC

Principales Noticias

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept 2024, 17:27 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept 2024, 17:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 sept 2024, 17:00 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in August -- Market Talk

6 sept 2024, 16:36 UTC

Charlas de Mercado

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept 2024, 16:35 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept 2024, 16:33 UTC

Adquisiciones, fusiones, absorciones

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept 2024, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

6 sept 2024, 16:20 UTC

Ganancias

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept 2024, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

92.11% repunte

Estimación a 12 meses

Media 15.33 USD 92.11%

Máximo 30 USD

Mínimo 7 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

6.1 / 7.65Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

308 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.